New US Platform Programme Account Opened

RNS Number : 4257F

Deltex Medical Group PLC

12 November 2015

 

12 November 2015

Deltex Medical Group plc

("Deltex Medical" or "the Company")

New US platform programme account opened

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added a new platform programme account in the USA.

The account is a major West Coast teaching hospital which has been an ad hoc customer of the Company for five years. It has now agreed to expand its usage of the Deltex ODM system with a goal of purchasing 100 probes per month as it rolls out ODM adoption in surgery within its enhanced recovery programme, in critical care and paediatrics. The Company is installing new monitors, introducing its e-learning and simulation packages and supporting the hospital with a tailored dedicated training programme.

It is the third platform programme account for the Company on the US West Coast, the Company's longest established US sales region and the first new platform programme account in the territory since hiring a clinical trainer in the Northern (San Francisco) part of the territory in June 2015.

This brings the total number of US platform programme accounts to 13, of which seven are new in the year, further illustrating the success of the Company's ongoing strategy to focus on the USA and develop it as a key market.

Earlier this month, the hospital became the first US hospital to order paediatric probes since the Company formally launched its paediatric technology at the Society for Pediatric Anesthesia meeting in San Diego last month.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"We are pleased to have this, the 7th account added to our US platform programme this year and the 13th in total and we are making good progress towards our current goal of 30 US hospitals on our platform programme by mid-2016. The US continues to be an increasingly important market for us and we see it becoming our key territory for development as adoption rates continue to outperform other territories. We look forward to working with the team at this important new account."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Finance Director Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie Ciaran Walsh
Joint Broker Zeus Capital Limited Phil Walker Dominic Wilson	020 3829 5000
Financial Public Relations
IFC Advisory	0203 053 8671
Tim Metcalfe Graham Herring Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

MSCGGGRCGUPAGMG